– Sonelokimab, a bivalent nanobody targeting IL-17A and IL-17F, met the primary endpoint (ACR50 at week 12) in active psoriatic arthritis (PsA) at both 60 mg and 120 mg doses with induction dosing.
– High rates of ACR20, PASI90 and composite high‑threshold outcomes (ACR70+PASI100, minimal disease activity) were observed through 24 weeks in sonelokimab-treated patients.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
